Last reviewed · How we verify
Hexanium (HEXAMETHONIUM)
Hexanium (generic name: HEXAMETHONIUM) is a hexamethonium drug. It is currently in Phase 2 development.
Hexamethonium works by blocking the action of acetylcholine at nicotinic receptors in the autonomic nervous system.
Hexamethonium, also known as Hexanium, is a small molecule drug that targets the neuronal acetylcholine receptor subunit alpha-4. It belongs to the hexamethonium class and is used to treat conditions related to the autonomic nervous system. However, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to determine its potential as a therapeutic agent. As a result, its current status in the pharmaceutical market is unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HEXAMETHONIUM |
|---|---|
| Drug class | hexamethonium |
| Target | Neuronal acetylcholine receptor subunit alpha-6, Neuronal acetylcholine receptor subunit alpha-4, Neuronal acetylcholine receptor; alpha4/beta2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of acetylcholine as a key that unlocks a door in the nervous system. Hexamethonium is like a lock that prevents the key from turning, effectively blocking the signal that can cause certain bodily functions to occur. This can help to reduce symptoms associated with conditions such as hypertension and certain types of arrhythmias.
Approved indications
Common side effects
Key clinical trials
- Safety and Performance of the Hexanium TLIF System in the Treatment of Degenerative Disc Disease
- Safety and Performance of the SPINEVISION Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease
- Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) (PHASE1)
- Effect of Depressin Screening and Care Program at Community Health Center (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hexanium CI brief — competitive landscape report
- Hexanium updates RSS · CI watch RSS
Frequently asked questions about Hexanium
What is Hexanium?
How does Hexanium work?
What is the generic name of Hexanium?
What drug class is Hexanium in?
What development phase is Hexanium in?
What does Hexanium target?
Related
- Drug class: All hexamethonium drugs
- Target: All drugs targeting Neuronal acetylcholine receptor subunit alpha-6, Neuronal acetylcholine receptor subunit alpha-4, Neuronal acetylcholine receptor; alpha4/beta2
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing